Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 43k research works in it since 1950. 17.3% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the diagnosis, management, and pathogenesis of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. It covers evidence-based guidelines, cellular and molecular mechanisms of fibrosis, therapeutic translation, treatment trials with drugs like pirfenidone and nintedanib, as well as the role of myofibroblasts and epithelial-mesenchymal transition in lung fibrosis.
- Idiopathic Pulmonary Fibrosis
- Fibrosis
- Interstitial Lung Disease
- TGF-ß
- Myofibroblast
- Pirfenidone
- Nintedanib
- Epithelial-Mesenchymal Transition
- Lung Fibrosis
- Bronchoalveolar Lavage
- Research works
- 43k fractional, since 1950
- In the world top 10%
- 7.5k per year above
- Top-10% rate
- 17.3% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +46% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis research?
By volume, the United States and China publish the most (2.2k and 1.8k works in 2022–2025).
By volume, 2022–2025
- 1 United States 2.2k works
- 2 China 1.8k works
- 3 Japan 779 works
- 4 United Kingdom 508 works
- 5 Germany 409 works
- 6 India 399 works
- 7 Italy 390 works
- 8 France 343 works
- 9 Spain 326 works
- 10 South Korea 263 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis research?
By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis research, followed by Imperial College London and University of Michigan.
By volume, 2022–2025
- 1 Chinese Academy of Medical Sciences & Peking Union Medical College China 48 works
- 2 Imperial College London United Kingdom 42 works
- 3 University of Michigan United States 39 works
- 4 Inserm France 35 works
- 5 Sichuan University China 34 works
- 6 University of Colorado Denver United States 31 works
- 7 University of Pittsburgh United States 27 works
- 8 University of Alabama at Birmingham United States 27 works
- 9 Yale University United States 27 works
- 10 Capital Medical University China 27 works
Where is Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis research done?
The largest centres of Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis research in 2022–2025 are Beijing (China), Tokyo (Japan), London (United Kingdom) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Hamamatsu.
Largest cities, 2022–2025
Where it is the local speciality
- HamamatsuJP · 26.8 works22×
Location quotient: how much more of its research is in Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis than the world average.
Where is the best place to study Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis?
Among universities, judged by research, Hamamatsu University School of Medicine, China Pharmaceutical University and University of Colorado Denver score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Hamamatsu University School of Medicine Japan | 59.3 | 22.5% | 29.8× | 15 | +164.9% |
| 2 | China Pharmaceutical University China | 59.0 | 52.6% | 4.7× | 10 | +234.1% |
| 3 | University of Colorado Denver United States | 58.7 | 19.3% | 10.4× | 31 | +54.3% |
| 4 | Beijing University of Chinese Medicine China | 56.9 | 28.6% | 8.1× | 13 | +191.7% |
| 5 | Imperial College London United Kingdom | 56.2 | 21.6% | 4.9× | 42 | +85.5% |
| 6 | Nanjing Medical University China | 53.8 | 37.5% | 4.4× | 21 | +128.6% |
| 7 | Capital Medical University China | 53.3 | 31.0% | 5.0× | 27 | +108.2% |
| 8 | Chinese Academy of Medical Sciences & Peking Union Medical College China | 52.6 | 26.0% | 5.4× | 48 | +19.3% |
| 9 | Medizinische Hochschule Hannover Germany | 52.5 | 14.2% | 11.2× | 22 | +46.3% |
| 10 | University of Colorado Anschutz Medical Campus United States | 52.5 | 23.1% | 6.2× | 16 | +268.3% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis research growing?
Output in 2018–2022 was 46% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.